MedTrace Logo

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

NCT06236672 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 348

Last updated 2024-02-01

No results posted yet for this study

Summary

The overall objective of this study is to compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist compared with adding basal insulin for patients with type 2 diabetes and chronic kidney disease, already treated with an sodium-glucose cotransporter-2 inhibitor and not currently reaching target glycemic control. All sociodemographic information and clinical variables will be retrieved from the LMC Diabetes Registry.

Conditions

Interventions

DRUG

GLP-1 receptor agonist

GLP-1 RA initiated between January 2019 and December 2022

DRUG

basal insulin

basal insulin initiated between January 2019 and December 2022

Sponsors & Collaborators

  • Novo Nordisk Canada Inc.

    collaborator UNKNOWN

  • LMC Diabetes & Endocrinology Ltd.

    lead OTHER

Principal Investigators

  • Alexander Abitbol, MD · LMC Diabetes & Endocrinology Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2023-11-29
Completion
2023-11-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236672 on ClinicalTrials.gov